Exec-Edge, Author at ExecEdge

VERAXA Biotech Shows Regulatory Progress on Cancer Therapy Platform

VERAXA Biotech Shows Regulatory Progress on Cancer Therapy Platform

  By Daniella Parra VERAXA Biotech said it received positive scientific advice from Germany’s Paul-Ehrlich-Institute supporting a preclinical development plan for its experimental BiTAC-TCE cancer therapy platform. The feedback provides greater regulatory clarity and reduces some early-stage development risk as...

Slate Medicines Appoints Mark W. Hahn to Board of Directors

Slate Medicines Appoints Mark W. Hahn to Board of Directors

By Daniella Parra Slate Medicines, a private biotech company developing new treatments for migraine and other headache disorders, has appointed Mark W. Hahn to its Board of Directors, they said. The company said Hahn brings more than 25 years of...

Acumen Pharmaceuticals Shows Early Alzheimer’s Disease Insights

Acumen Pharmaceuticals Shows Early Alzheimer’s Disease Insights

By Daniella Parra Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) said its Enhanced Brain Delivery (EBD) bispecific antibodies showed improved brain penetration in the treatment of Alzheimer’s disease. The company said it is collaborating with JCR Pharmaceuticals Co., Ltd. on EBD candidate development and studies through...

Input your search keywords and press Enter.